Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Autolus Therapeutics ( (AUTL) ).
Autolus Therapeutics has announced the FDA approval of its first product, AUCATZYL, a potentially best-in-class CD19 CAR T cell therapy indicated for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia. The approval, based on the FELIX trial, highlights the product’s novel mechanism of action and favorable safety profile, positioning Autolus for commercial execution and market expansion in the hemato-oncology sector.
More about Autolus Therapeutics
Autolus Therapeutics is a biotechnology company focused on developing next-generation programmed T cell therapies, particularly CAR-T therapies such as AUCATZYL, aiming to address hematological and autoimmune diseases with innovative mechanisms.
YTD Price Performance: -10.27%
Average Trading Volume: 1,883,931
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $628M
See more data about AUTL stock on TipRanks’ Stock Analysis page.